Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03241173 · ClinicalTrials.gov registry record · Phase 1
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
A Phase 1 study, sponsored by Incyte Biosciences International Sàrl.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT03241173 is a Phase 1 study that has completed, run by Incyte Biosciences International Sàrl. The registered enrollment target is 52 participants.
The verdict
NCT03241173, a Phase 1 study, has completed, sponsored by Incyte Biosciences International Sàrl.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01949 when given in combination with immune therapies in participants with advanced or metastatic malignancies.
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG INCAGN01949
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2017-10-09 |
| Est. Completion | 2019-09-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03241173
The ClinicalTrials.gov registry entry for NCT03241173 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Biosciences International Sàrl, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT03241173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03241173 about?
NCT03241173 is a clinical study titled "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies". The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01949 when given in combination with immune therapies in participants with advanced or metastatic malignancies.
What is the current status of trial NCT03241173?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2017-10-09. Estimated completion is 2019-09-17.
What interventions are being tested in trial NCT03241173?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), INCAGN01949 (DRUG).
Who is sponsoring clinical trial NCT03241173?
This trial is sponsored by Incyte Biosciences International Sàrl, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.